Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06990542 | Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer | PHASE2 | RECRUITING | 150 | — | — | Jun 9, 2025 | Dec 1, 2033 | Feb 17, 2026 | 1 | United States |
Acute any attribution genitourinary or gastrointestinal toxicity (grade 2 or higher), compared between randomized arms, defined as the percentage of patients with Common Terminology Criteria for Adverse Events genitourinary or gastrointestinal toxicity of grade 2 or higher within 3 months of completing radiation therapy. Based on the Common Terminology Criteria for Adverse Event, grade 1 is the lowest and grade 5 is the highest. Grade 5 represents the worst outcome (death).
| Arm | Type | Description |
|---|---|---|
| Standard of care dose radiotherapy | NO_INTERVENTION | Standard dose radiation therapy |
| Tumor-focused radiotherapy | EXPERIMENTAL | Image-guided tumor-focused radiation therapy |
| Name | Type | Description |
|---|---|---|
| Image-guided tumor-focused radiation therapy | RADIATION | Image-guided tumor-focused radiation therapy |
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * At least 18 years old * Histologic confirmation of prostate adenocarcinoma with plan for curative-intent radiation ther...